Page 3 - Recognify Life Sciences News Today : Breaking News, Live Updates & Top Stories | Vimarsana

email article The FDA approved the ADHD medication viloxazine extended-release capsules (Qelbree), a new selective norepinephrine reuptake inhibitor, for patients ages 6 to 17, Supernus Pharmaceuticals announced. In other FDA news, Acadia Pharmaceuticals received a complete response letter from the agency, which declined to approve pimavanserin (Nuplazid) for hallucinations and delusions associated with dementia-related psychosis due to a lack of statistical significance in certain subgroups of the phase III HARMONY study. The treatment was approved for hallucinations and delusions asso...

Recognify Life Sciences to Commence Phase 2a Study in Cognitive Impairment Associated with Schizophrenia News provided by Share this article Share this article NEW YORK, April 6, 2021 /PRNewswire/ -- Recognify Life Sciences, Inc. (Recognify), an atai Life Sciences (atai) platform company focused on developing treatments for cognitive impairment with initial efforts targeting Cognitive Impairment Associated with Schizophrenia (CIAS), today announced it has initiated a Phase 2a study for its lead compound RL-007, after receiving IND clearance from the Food and Drug Administration to commence c...

Over 90+ Schizophrenia pipeline therapies are under different stages of development and their expected approval in the Schizophrenia market shall uplift the market revenue significantly.  Out of emerging therapies, AVP-786 is in Phase II/III stage of trials. Similarly, MK-8189 is undergoing Phase II developmental phase for Schizophrenia.  Schizophrenia pipeline therapies in the early stages of development include CAD-9303, and In December 2020, FDA assigns PDUFA action date of (01/06/2021) for ALKS 3831 for Schizophrenia and Bipolar disorders. In June 2020, Neurocrine Biosciences and ...

Compass Launches Center Of Excellence Compass Pathways (NASDAQ:CMPS) officially launched the Centre of Excellence, in collaboration with The Sheppard Pratt Institute for Advanced Diagnostics and Therapeutics in Baltimore, Maryland. This “clinic model” will study and build the best therapy models for psychedelics treatment and work as a site for clinical trials as well as a laboratory for innovation. It will also explore research around COMP360, Compass’ psilocybin drug candidate. Scott Aaronson MD, Director of Clinical Research at Sheppard Pratt, will lead the center. “Sheppard P...